Background: Endobronchial metastases are rare. The most frequent primary tumors associated with endobronchial involvement are breast, colon and renal cell carcinomas. Metastases from colorectal cancers can be treated either surgically or with chemotherapy in order to improve survival. Objectives: This paper aims to report the potential role of interventional bronchoscopy in patients with endobronchial metastases from colorectal cancer. Methods: This retrospective study included 24 patients who underwent an interventional bronchoscopy procedure between 1988 and 2006. All patients had verified tracheobronchial metastases and were treated to relieve their obstruction. Assessment of the natural history of metastatic colorectal carcinoma, therapeutic options and survival associated with endobronchial metastases are reported. Results: Endobronchial metastases occurred at a median of 53 months (range 18–144) following the diagnosis of the primary tumor. Fifty-seven percent of patients had other proven metastases when the endobronchial involvement was diagnosed. All patients had known synchronous pulmonary metastases upon the discovery of tracheobronchial secondary lesions. The most frequently observed symptoms were dyspnea, cough and hemoptysis. Atelectasis was a common radiological finding. In 67% of patients, an interventional bronchoscopy was possible with the primary intent of relieving the obstruction. An endoscopic intervention provided symptomatic relief and an improvement in forced expiratory volume in 1 s. The median overall survival was 70 months (range 23–245) and 14 months once the endobronchial metastase(s) had been diagnosed. Conclusion: Endobronchial metastases occur relatively late in patients with a metastatic colorectal neoplasm. Palliative treatment with interventional bronchoscopy to prevent asphyxia is a safe and effective method that may improve the quality of life in these patients.

1.
Braman SS, Whitcomb ME: Endobronchial metastasis. Arch Intern Med 1975;135:543–547.
2.
Kiryu T, Hoshi H, Matsui E, et al: Endotracheal/endobronchial metastases. Chest 2001;119:768–775.
3.
Sørensen JB: Endobronchial metastases from extrapulmonary solid tumors. Acta Oncol 2004;43:73–79.
4.
Berg HK, Petrelli NJ, Herrera L, et al: Endobronchial metastasis from colorectal carcinoma. Dis Colon Rectum 1984;27:745–748.
5.
De Vita V, Hellman S, Rosenberg S: Cancer: Principles and Practice of Oncology: Cancer of the Colon, ed 6. Philadelphia, Lippincott, 2000, pp 33–77.
6.
Sobin LH, Wittekind CH, Wiley J: UICC/TNM Classification of Malignant Tumours, ed 6. Berlin, Springer, 2002.
7.
Ormerod LP, Horsfield N, Alani FS: How frequently do endobronchial secondaries occur in an unselected series? Respir Med 1998;92:599–600.
8.
Rovirosa Casino A, Bellmunt J, et al: Endobronchial metastases in colorectal adenocarcinoma. Tumori 1992;78:270–273.
9.
Carlin BW, Harrell JH 2nd, Olson LK, et al: Endobronchial metastases due to colorectal carcinoma. Chest 1989;96:1110–1114.
10.
Salud A, Porcel JM, Rovirosa A, Bellmunt J: Endobronchial metastatic disease: analysis of 32 cases. J Surg Oncol 1996;62:249–252.
11.
Heitmiller RF, Marasco WJ, Hruban RH, et al: Endobronchial metastasis. J Thorac Cardiovasc Surg 1993;106:537–542.
12.
Graf W, Glimelius B, Pahlman L, et al: Determinants of prognosis in advanced colorectal cancer. Eur J Cancer 1991;27:1119–1123.
13.
Buyse M, Thirion P, Carlson RW, et al: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Lancet 2000;356:373–378.
14.
Litle VR, Christie NA, Fernando HC, et al: Photodynamic therapy for endobronchial metastases from nonbronchogenic primaries. Ann Thorac Surg 2003;76:370–375.
15.
Katsimbri PP, Bamias AT, Froudarakis ME, et al: Endobronchial metastases secondary to solid tumors: report of eight cases and review of the literature. Lung Cancer 2000;28:163–170.
16.
Lee YC, Wong CS, Jeffery GM: Endobronchial metastasis from rectal adenocarcinoma. Respir Med 1997;91:245–248.
17.
Colletti PM, Beck S, Boswell WD Jr, et al: Computed tomography in endobronchial neoplasms. Comput Med Imaging Graph 1990;14:257–262.
18.
Wahadi MM, Herth FJ, Ernst A: State of the art: interventional pulmonology. Chest 2007;131:261–274.
19.
Cavaliere S, Venuta F, Foccoli P, et al: Endoscopic treatment of malignant airway obstruction in 2,008 patients. Chest 1996;110:1536–1542.
20.
Nassiri AH, Dutau H, Breen D, et al: A multicenter retrospective study investigating the role of interventional bronchoscopic techniques in the management of endobronchial lipomas. Respiration 2008;75:79–84.
21.
Vergnon JM, Huber RM, Moghissi K: Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur Respir J 2006;28:200–218.
22.
Bertoletti L, Elleuch R, Kaczmarek D, et al: Bronchoscopic cryotherapy treatment of isolated endoluminal typical carcinoid tumor. Chest 2006;130:1405–1411.
23.
Boxem T, Muller M, Venmans B, et al: Nd-YAG laser versus bronchoscopic electrocautery for palliation of symptomatic airway obstruction. Chest 1999;116:1108–1112.
24.
Chetty KG, Moran EM, Sassoon CS: Effect of radiation therapy on bronchial obstruction due to bronchogenic carcinoma. Chest 1989;95:582–584.
25.
Kelly JF, Delclos ME, Morice RC, et al: High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year MD Anderson cancer center experience. Int J Radiat Oncol Biol Phys 2000;48:697–702.
26.
Parrat E, Pujol JL, Gautier V, et al: Chest tumor response during lung cancer chemotherapy: computed tomography versus fiberoptic bronchoscopy. Chest 1993;103:1495– 1501.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.